Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics

Royalty Pharma (RPRX) reported $735 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 15.4%. EPS of $1.04 for the same period compares to $0.79 a year ago.The reported revenue represents a surprise of +3.39% over the Zacks Consensus Estimate of $710.89 million. With the consensus EPS estimate being $0.95, the EPS surprise was +9.47%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Royalty Receipts- Growth Products- Cystic fibrosis franchise: $206.99 million versus the two-analyst average estimate of $199.79 million. The reported number represents a year-over-year change of -13%. Revenue- Royalty Receipts- Growth Products- Tysabri: $68.26 million compared to the $68.32 million average estimate based on two analysts. The reported number represents a change of -21.3% year over year. Revenue- Royalty Receipts- Growth Products- Imbruvica: $46.20 million versus the two-analyst average estimate of $45.92 million. The reported number represents a year-over-year change of -25.7%. Revenue- Royalty Receipts- Growth Products- Xtandi: $43.31 million versus the two-analyst average estimate of $42.19 million. The reported number represents a year-over-year change of -8.1%. Revenue- Royalty Receipts- Growth Products- Promacta: $41.81 million versus the two-analyst average estimate of $43.21 million. The reported number represents a year-over-year change of -22.8%. Revenue- Royalty Receipts- Growth Products- Tremfya: $34.26 million versus the two-analyst average estimate of $35.78 million. The reported number represents a year-over-year change of +26%. Revenue- Milestones and other contractual receipts: $3 million compared to the $4.50 million average estimate based on two analysts. Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq: $18.53 million versus $19.33 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change. Revenue- Royalty Receipts- Growth Products- Evrysdi: $47.95 million versus the two-analyst average estimate of $46.73 million. The reported number represents a year-over-year change of +204.5%. Revenue- Royalty Receipts- Growth Products- Trodelvy: $11.47 million versus $11.27 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change. Revenue- Total Royalty Receipts- Growth Products: $731.74 million versus $706.39 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change. Revenue- Royalty Receipts- Growth Products- Trelegy: $90.54 million versus $90.67 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.5% change. View all Key Company Metrics for Royalty Pharma here>>>Shares of Royalty Pharma have returned +0.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royalty Pharma PLC (RPRX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks